Vivo Capital

About This Fund

Vivo Capital is an institutional investor (Conventional VCs,) founded in 1996 and headquartered in Palo Alto, California, United States (and 4 other locations). Vivo Capital is a global healthcare investment platform founded in 1996, managing over $7.2 billion in assets. The firm has invested in 460+ healthcare companies across therapeutics, medical devices, diagnostics, and healthcare services. Vivo operates dedicated strategies spanning venture capital, private equity, and public equity investments. Global investment firm. It is focused on the healthcare sector, with investment platforms in venture capital, growth private equity, control acquisitions and public market investments. Fund Philosophy: Vivo is a global healthcare investment platform that seeks to foster innovation and growth in the global healthcare market via its unique Ecosystem Approach. The firm invests globally and seeks to create value and proprietary investment opportunities by tapping into the ecosystem of portfolio companies and resources within its network, facilitating international partnerships and cross-value chain collaborations. Practice areas include Investment Industry. The firm operates as Venture Capital Funds and Private Equity Funds. Key investment sectors include Healthcare / HealthTech. The firm typically invests at the Growth, Private Equity, and Public Market stage(s). Geographic focus spans Global. Assets Under Management (AUM): $7.2 billion. Notable portfolio companies: Hutchison MediPharma, SciClone Pharmaceuticals (NASDAQ:SCLN), Circassia, Akeso (SEHK:9926), CStone Pharmaceuticals (SEHK:2616), Zai Lab (NASDAQ:ZLAB), Adagene (NASDAQ:ADAG), Connect Biopharma (NASDAQ:CNTB), Innova Medical Group, Avid Bioservices (NASDAQ:CDMO), Terns Pharmaceuticals (NASDAQ:TERN).

Investment Focus